About this document
2021 - What To Use To Treat AML The Role of Emerging Therapies by BCR ABL is a document available to read on EtoBox.
The document discusses advancements in the treatment of acute myeloid leukemia (AML), highlighting the importance of genetic and molecular testing for personalized therapy. Key therapies include midostaurin for FLT3-mutated AML, gilteritinib for relapsed cases, and novel agents like gemtuzumab ozogamicin and CPX-351 for specific patient populations. The document emphasizes the evolving treatment landscape and the need for tailored approaches based on genetic profiles and patient characteristics.
- Author
- BCR ABL
- Language
- EN